Evidence map›Paper›PMID 35939999›Full record

ArticleJournal of psychiatric research2022

Drug use trajectories among U.S. adults during the first year of the COVID-19 pandemic.

Kira E Riehm, Junhan Cho, Emily J Smail, Eric Pedersen, Jungeun Olivia Lee, Jordan P Davis, Adam M Leventhal

Open access · greenAbstract read
In one paragraph

Article in Journal of psychiatric research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kira E RiehmDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: kr2976@cumc.columbia.edu.
Junhan ChoInstitute for Addiction Science, University of Southern California, Los Angeles, CA, USA; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Emily J SmailDepartment of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL, USA.
Eric PedersenInstitute for Addiction Science, University of Southern California, Los Angeles, CA, USA; Department of Psychiatry and Behavioral Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Jungeun Olivia LeeSuzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA, USA.
Jordan P DavisSuzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA, USA.
Adam M LeventhalInstitute for Addiction Science, University of Southern California, Los Angeles, CA, USA; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Department of Psychology, University of Southern California Dana and David Dornsife College of Letters, Arts, and Sciences, Los Angeles, CA, USA.
University of Southern California · USColumbia University Irving Medical Center · USUniversity of Florida Health · US

Funding

Tobacco Use Treatment Research for Vulnerable PopulationsK24DA048160 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Adam Matthew Leventhal · 2019 to 2026
$1.4M
NIDA NIH HHS K24 DA048160
6 · The paper itself

Abstract

This study characterized the prevalence, sociodemographic characteristics, and behavioral health of U.S. adult subpopulations with distinct drug use trajectories during the first year of the COVID-19 pandemic. Adult respondents (n = 8306) in a nationally-representative longitudinal study completed 13 monthly web surveys (March 2020-March 2021). Frequency of past-week drug use, cannabis use, and alcohol use (range:0-7), as well as anxiety and depressive symptoms, were assessed at each survey. Growth mixture models were used to parse out distinct subpopulations with homogenous drug use trajectories based on mean drug use days over time. Four drug use trajectories were identified: Stable Abstinence (85.7% [95%CI = 85.0-86.5] of the sample) with <1 mean past-week drug use days; Escalating Infrequent Use (7.1% [95%CI = 6.6-7.7]) with 0.2 March mean past-week drug use days and increases from April to October; Use Cessation (4.3% [95%CI = 3.8-4.7]) with 1.1 March mean past-week drug use days that initially increased, then sharply decreased to near zero; and Stable Frequent Use (2.9% [95%CI = 2.5-3.3]) with between 2.4 and 3.5 past-week drug use days across the study period. Compared to the stable abstinence group, the other subgroups were more likely to be Hispanic or Black, younger in age, unemployed, below the federal poverty line, and less likely to have a college degree or be married. They also reported higher levels of alcohol and cannabis use, as well as higher anxiety and depressive symptoms. These results provide opportunities to optimize the targeted delivery of preventive interventions for substance use during the COVID-19 pandemic and future public health emergencies.

Indexed as

COVID-19Substance-Related DisordersAdultAnxietyHumansLongitudinal StudiesPandemicsCOVID-19 pandemicDrug useEpidemiologySubstance use

Identifiers

PMID35939999
PMCPMC9339074
OpenAlexW4288926645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.